Health Boards
This study suggest that patients over 90 kg could benefit from moving to a two week between shots regime with Cosentyx (secukinumab).
Source: onlinelibrary.wiley.com
*Early view funding unknown.
Cosentyx (secukinumab)
On a personal note. I tried 3 weeks between shots for 6 months to try and clear up the odd bit of psoriasis I keep getting on my legs and it made no difference. I went back to 4 weeks, but will point out that I am taking Cosentyx for psoriatic arthritis and can live with the odd little bit of psoriasis.
Quote:
Background:
Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralises interleukin‐17A.
Objective:
To assess the efficacy and safety of different maintenance‐dosing regimens of secukinumab 300 mg based on PASI response at Week 24 in patients with moderate to severe plaque psoriasis.
Methods:
OPTIMISE was a randomised, open‐label, rater‐blinded Phase 3b study. Subjects (n=1,647) received secukinumab 300 mg at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks (q4w) to Week 24. At Week 24, PASI 90 responders (n=1306) were randomised to secukinumab 300 mg q4w (n=644) or every 6 weeks (q6w, n=662) regimen to Week 52; PASI ≥75 to <90 responders (n= 206) were randomised to secukinumab 300 mg q4w (n=114) or every 2 weeks (q2w, n=92) regimen to Week 52.
Results:
PASI 90 response was maintained at Week 52 by 85.7% subjects with q4w dosing vs 74.9% with q6w dosing; odds ratio 1.91 (95% confidence interval 1.44, 2.55). The primary endpoint, non‐inferiority of q6w vs q4w dosing, was not met. In PASI ≥75 to <90 responders, the proportion of subjects with PASI 90 response at Week 52 was numerically higher in q2w vs. q4w group (56.5% vs. 46.5%, respectively; P=0.1013). Heavier subjects (≥90 kg) demonstrated numerically higher PASI 90 response with q2w (57.1%) vs q4w regimen (39.6%, P=0.1053).
Conclusion:
Standard q4w dosing of secukinumab 300 mg is the optimal dosing regimen to achieve and maintain clear or almost clear skin. Subjects with body weight ≥90 kg not achieving PASI 90 at Week 24 may benefit from the q2w dosing regimen.
Source: onlinelibrary.wiley.com
*Early view funding unknown.
Cosentyx (secukinumab)
On a personal note. I tried 3 weeks between shots for 6 months to try and clear up the odd bit of psoriasis I keep getting on my legs and it made no difference. I went back to 4 weeks, but will point out that I am taking Cosentyx for psoriatic arthritis and can live with the odd little bit of psoriasis.